424B3

424B3 1 d86661d424b3.htm 424B3 424B3

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-279367

Prospectus Supplement

(To Prospectus dated May 23, 2024)

LOGO

This prospectus supplement supplements and amends the prospectus dated May 23, 2024 (the “Prospectus”), as supplemented and amended by that certain prospectus supplement dated November 19, 2024 covering the offering, issuance and sale of up to a maximum aggregate offering price of $100,000,000 (the “Maximum Offering Price”) of our common stock that may be issued and sold under an Open Market Sale Agreement^SMwith Jefferies LLC (the “ATM Facility”).

Effective as of February 20, 2026, we have reduced the Maximum Offering Price to $0. As of the date of this prospectus supplement, no shares have been sold under the ATM Facility.

You should read this prospectus supplement, together with additional information described under the headings “Information Incorporated by Reference” and “Where You Can Find Additional Information” in the Prospectus carefully before you invest in our securities.

Investing in our securities involves a high degree of risk. Before making any investment in our securities, you should consider carefully the risks and uncertainties described in the section entitled “Risk Factors” beginning on page 7 of the Prospectus.

The date of this prospectus supplement is February 20, 2026.

SEC Form 424B3 filed by Atossa Therapeutics Inc.